The impact upon extra‐pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia
Year: 2003
Type: article
Study design: Clinical Trial
DOI: 10.1002/gps.862
Authors: C. W. Ritchie, E. Chiu, S. Harrigan, K. Hall, A. Hassett, S. Macfarlane, M. Mastwyk, D. W. O'Connor, J. Opie, D. Ames
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Keywords: olanzapine, risperidone, atypical antipsychotics, typical antipsychotics, schizophrenia, elderly patients, antipsychotic switching, parkinsonism, dyskinesia, quality of life, negative symptoms, depression, treatment failure, crossover trial, antipsychotic efficacy and safety, dose reduction, WHOQOL-BREF
Open Access status: closed
Funder: Eli Lilly and Company
OpenAlex ID: W2075039588
